Immune checkpoint inhibitors in challenging populations

Cancer

Volumn 123, Issue 11, 2017, Pages 1904-1911

  Johnson, Douglas B ^a   Sullivan, Ryan J ^b   Menzies, Alexander M ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

autoimmune; elderly; ipilimumab; nivolumab; organ dysfunction; pediatrics; pembrolizumab; pregnancy; transplant

Indexed keywords

ATEZOLIZUMAB; CHECKPOINT KINASE INHIBITOR; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLADDER CARCINOMA; BRAIN METASTASIS; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; MULTIPLE ORGAN FAILURE; MYOCARDITIS; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; NONHUMAN; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PREGNANCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VIRUS INFECTION; AGE; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEAD AND NECK NEOPLASMS; IMMUNOCOMPROMISED PATIENT; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; PREGNANCY COMPLICATIONS, NEOPLASTIC; SECONDARY;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; CTLA-4 ANTIGEN; FEMALE; GRAFT REJECTION; HEAD AND NECK NEOPLASMS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSPLANT RECIPIENTS;

EID: 85013892577     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30642     Document Type: Review

References (75)

1. Wolchok JD. PD-1 blockers. Cell. 2015;162:937.
2. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
3. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–988.
4. Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002;32:666–669.
5. Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A. 2016;113:E2383–E2392.
6. Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2:1507–1508.
7. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234–240.
8. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti–PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016 Sep 29. doi: 10.1093/annonc/mdw443. [Epub ahead of print]
9. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007;179:5204–5210.
10. Shi XL, Mancham S, Hansen BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. J Hepatol. 2016;64:1274–1282.
11. Forconi C, Gatault P, Miquelestorena-Standley E, et al. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors. J Heart Lung Transplant. 2016 Aug 26. doi: 10.1016/j.healun.2016.08.014. [Epub ahead of print]
12. Schade H, Sen S, Neff CP, et al. Programmed death 1 expression on CD4 + T cells predicts mortality after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:2172–2179.
13. Saha A, O'Connor RS, Thangavelu G, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642–2660.
14. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1581–1588.
15. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143–153.
16. Herz S, Hofer T, Papapanagiotou M, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer. 2016;67:66–72.
17. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135–1137.
18. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer. 2015;3:22.
19. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother. 2015;38:211.
20. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69–e71.
21. Jose A, Yiannoullou P, Bhutani S, et al. Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature. Transplant Proc. 2016;48:3137–3141.
22. Aslan A, Aras T, Ozdemir E. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation. Leuk Lymphoma. 2017;58:754–755.
23. Shad AT, Huo JS, Darcy C, et al. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr Blood Cancer. 2017;64:26257.
24. Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850–852.
25. Angenendt L, Schliemann C, Lutz M, et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:443–445.
26. Villasboas JC, Ansell SM, Witzig TE. Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget. 2016;7:13260–13264.
27. Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant. 2016;16:2496–2497.
28. Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer. 2016;4:64.
29. Owonikoko TK, Kumar M, Yang S, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother. 2017;66:45–50.
30. Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol. 2016;95:1913–1915.
31. Singh AK, Porrata LF, Aljitawi O, et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant. 2016;51:1268–1270.
32. Kwong YL. Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol. 2016;95:1191–1192.
33. Lipson EJ, Bagnasco SM, Moore J Jr, et al. Tumor regression and allograft rejection after administration of anti–PD-1. N Engl J Med. 2016;374:896–898.
34. Jeong HY, Lee YJ, Seo SK, et al. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J Leukoc Biol. 2008;83:755–764.
35. Lukens JR, Cruise MW, Lassen MG, Hahn YS. Blockade of PD-1/B7-H1 interaction restores effector CD8 + T cell responses in a hepatitis C virus core murine model. J Immunol. 2008;180:4875–4884.
36. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198–1202.
37. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–354.
38. Davar D, Wilson M, Pruckner C, Kirkwood JM. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med. 2015;2015:737389.
39. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015;33:LBA101.
40. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
41. Weber JS, D'Angelo SP, Minor DM, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
42. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–465.
43. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies—mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007;10:84–96.
44. Kanz BA, Pollack MH, Johnpulle R, et al. Safety and efficacy of anti–PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016;4:60.
45. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.
46. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.
47. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.
48. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–1389.
49. Kaur A, Webster MR, Marchbank K, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532:250–254.
50. Bethof A, Nipp R, Rubin K, et al. Age on outcome and toxicity with anti–PD-1/PD-L1 therapy in patients with melanoma [abstract]. Pigment Cell Melanoma Res. 2015;28:756.
51. Rai R, McQuade JL, Wang DY, et al. Safety and efficacy of anti–PD-1 antibodies in elderly patients with metastatic melanoma. Ann Oncol. 2016;27(suppl 6):379–400.
52. Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37.
53. Johnpulle RA, Conry RM, Sosman JA, Puzanov I, Johnson DB. Responses to immune checkpoint inhibitors in nonagenarians. Oncoimmunology. 2016;5:e1234572.
54. Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22:1364–1370.
55. Aoki T, Hino M, Koh K, et al. Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer. 2016;63:1461–1464.
56. Ring EK, Markert JM, Gillespie GY, Friedman GK. Checkpoint proteins in pediatric brain and extracranial solid tumors: opportunities for immunotherapy. Clin Cancer Res. 2017;23:342–350.
57. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
58. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4:959–967.
59. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124–128.
60. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32.
61. Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219.
62. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Survival among non–small cell lung cancer patients with poor performance status after first line chemotherapy. Lung Cancer. 2012;77:545–549.
63. Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–784.
64. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542–2552.
65. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–319.
66. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
67. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600–1609.
68. Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.
69. Dagogo-Jack I, Lanfranchi M, Gainor JF, et al. A retrospective analysis of the efficacy of pembrolizumab in melanoma patients with brain metastases. J Immunother. In press.
70. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non–small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976–983.
71. Alomari AK, Cohen J, Vortmeyer AO, et al. Possible interaction of anti–PD-1 therapy with the effects of radiosurgery on brain metastases. Cancer Immunol Res. 2016;4:481–487.
72. Liniker E, Menzies AM, Kong BY, et al. Activity and safety of radiotherapy with anti–PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5:e1214788.
73. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti–PD-1 therapy. Ann Oncol. 2016;27:434–441.
74. D'Addio F, Riella LV, Mfarrej BG, et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 2011;187:4530–4541.
75. Poulet FM, Wolf JJ, Herzyk DJ, DeGeorge JJ. An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors. Birth Defects Res B Dev Reprod Toxicol. 2016;107:108–119.